Product
Envafolimab
Aliases
Envafolimab Injection, Envafolimab with new manufacturing process, Envafolimab with old manufacturing process, KN035
14 clinical trials
16 indications
Indication
Healthy MaleIndication
Solid TumorIndication
Endometrial CancerIndication
Advanced SarcomaIndication
Metastatic SarcomaIndication
Soft Tissue SarcomaIndication
Lung CancerIndication
Malignant TumorsIndication
Biliary Tract NeoplasmsIndication
Undifferentiated Pleomorphic SarcomaIndication
MyxofibrosarcomaIndication
NSCLCIndication
Mucosal MelanomaIndication
Efficacy and SafetyIndication
Cervical CancerClinical trial
A Randomized, Double-blind, Single-dose, Parallel Controlled Phase I Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Envafolimab in Healthy Male Subjects Before and After the Manufacturing Process ChangeStatus: Recruiting, Estimated PCD: 2023-11-23
Clinical trial
An Open, Single-arm, Multi-center Phase II Clinical Study of ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-08-30
Clinical trial
An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial CancerStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 1/2 Study of YH001 in Combination With Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic SarcomaStatus: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Phase II Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced Non-Small Cell Lung Cancer(NSCLC).Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase I/II, Open-label, Dose Escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of LM-101 Injection as a Single Agent or Combination Therapy in Patients With Advanced Malignant TumorsStatus: , Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Open-Label, Multicenter Phase 2 Study of Envafolimab in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients With Locally Advanced or Metastatic Biliary Tract CancersStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
ENVASARC: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior ChemotherapyStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Single-arm, Exploratory Clinical Trial Investigating the Efficacy of Local Envafolimab Injection Under Fiberoptic Bronchoscopy Combined With Chemotherapy in Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-01-18
Clinical trial
Single-arm II Phase Study of Envafolimab Combined With Recombinant Human Endostatin and First-line ChemotherapyStatus: Not yet recruiting, Estimated PCD: 2025-09-18
Clinical trial
Prospective Clinical Study of Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell CarcinomaStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal CancerStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Controlled Clinical Study of Envafolimab (PD-L1 Antibody) Subcutaneous Injection Combined With Endostar and Concurrent Chemoradiotherapy in Treatment of Locally Advanced Primary Cervical CancerStatus: Not yet recruiting, Estimated PCD: 2024-05-16
Clinical trial
A Prospective, Two Cohort, Multicenter Phase II Clinical Study of Envafolimab Combined With Concurrent Chemoradiotherapy and Immune Maintenance Therapy For Limited Stage Small Cell Lung CancerStatus: Not yet recruiting, Estimated PCD: 2026-12-30